Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Apr. 30, 2021 | Jun. 11, 2021 | |
Cover [Abstract] | ||
Entity Registrant Name | NON INVASIVE MONITORING SYSTEMS INC /FL/ | |
Entity Central Index Key | 0000720762 | |
Document Type | 10-Q | |
Document Period End Date | Apr. 30, 2021 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --07-31 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | No | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business Flag | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | true | |
Entity Common Stock, Shares Outstanding | 154,810,655 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2021 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Apr. 30, 2021 | Jul. 31, 2020 |
Current assets | ||
Cash | $ 61 | $ 203 |
Prepaid expenses | 15 | 3 |
Total current assets | 76 | 206 |
Total assets | 76 | 206 |
Current liabilities | ||
Accounts payable and accrued expenses | 235 | 238 |
Current liabilities - discontinued operations | 50 | 50 |
Total current liabilities | 285 | 288 |
Total liabilities | 285 | 288 |
Commitments and contingencies (Note 7) | ||
Shareholders' deficit | ||
Series B Preferred Stock, par value $1.00 per share; 100 shares authorized, issued and outstanding; liquidation preference $10 | ||
Common Stock, par value $0.01 per share; 400,000,000 shares authorized; 154,810,655 shares issued and outstanding | 1,548 | 1,548 |
Additional paid in capital | 26,574 | 26,574 |
Accumulated deficit | (28,331) | (28,204) |
Total shareholders' deficit | (209) | (82) |
Total liabilities and shareholders' deficit | $ 76 | $ 206 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Apr. 30, 2021 | Jul. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Series B Preferred stock, par value | $ 1 | $ 1 |
Series B Preferred stock, shares authorized | 100 | 100 |
Series B Preferred stock, shares issued | 100 | 100 |
Series B Preferred stock, shares outstanding | 100 | 100 |
Series B Preferred stock, liquidation preference | $ 10 | $ 10 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 400,000,000 | 400,000,000 |
Common stock, shares issued | 154,810,655 | 154,810,655 |
Common stock, shares outstanding | 154,810,655 | 154,810,655 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Apr. 30, 2021 | Apr. 30, 2020 | Apr. 30, 2021 | Apr. 30, 2020 | |
Operating costs and expenses | ||||
General and administrative | $ 29 | $ 40 | $ 127 | $ 139 |
Total operating costs and expenses | 29 | 40 | 127 | 139 |
Operating loss | (29) | (40) | (127) | (139) |
Loss from continuing operations | (29) | (40) | (127) | (139) |
Gain from discontinued operations | 1 | |||
Net loss | $ (29) | $ (40) | $ (127) | $ (138) |
Weighted average number of common shares outstanding - Basic and diluted | 154,811 | 154,811 | 154,811 | 154,811 |
Basic and diluted loss per common share from continuing operations | $ 0 | $ 0 | $ 0 | $ 0 |
Basic and diluted loss per common share from discontinued operations | 0 | 0 | 0 | 0 |
Basic and diluted loss per common share | $ 0 | $ 0 | $ 0 | $ 0 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands | Series B Preferred Stock [Member] | Common Stock [Member] | Additional Paid in Capital [Member] | Accumulated Deficit [Member] | Total |
Balance, beginning at Jul. 31, 2019 | $ 1,548 | $ 26,574 | $ (28,041) | $ 81 | |
Balance, beginning shares at Jul. 31, 2019 | 100 | 154,810,655 | |||
Net loss | (55) | (55) | |||
Balance, ending at Oct. 31, 2019 | $ 1,548 | 26,574 | (28,096) | 26 | |
Balance, ending shares at Oct. 31, 2019 | 100 | 154,810,655 | |||
Balance, beginning at Jul. 31, 2019 | $ 1,548 | 26,574 | (28,041) | 81 | |
Balance, beginning shares at Jul. 31, 2019 | 100 | 154,810,655 | |||
Net loss | (138) | ||||
Balance, ending at Apr. 30, 2020 | $ 1,548 | 26,574 | (28,179) | (57) | |
Balance, ending shares at Apr. 30, 2020 | 100 | 154,810,655 | |||
Balance, beginning at Oct. 31, 2019 | $ 1,548 | 26,574 | (28,096) | 26 | |
Balance, beginning shares at Oct. 31, 2019 | 100 | 154,810,655 | |||
Net loss | (43) | (43) | |||
Balance, ending at Jan. 31, 2020 | $ 1,548 | 26,574 | (28,139) | (17) | |
Balance, ending shares at Jan. 31, 2020 | 100 | 154,810,655 | |||
Net loss | (40) | (40) | |||
Balance, ending at Apr. 30, 2020 | $ 1,548 | 26,574 | (28,179) | (57) | |
Balance, ending shares at Apr. 30, 2020 | 100 | 154,810,655 | |||
Balance, beginning at Jul. 31, 2020 | $ 1,548 | 26,574 | (28,204) | (82) | |
Balance, beginning shares at Jul. 31, 2020 | 100 | 154,810,655 | |||
Net loss | (59) | (59) | |||
Balance, ending at Oct. 31, 2020 | $ 1,548 | 26,574 | (28,263) | (141) | |
Balance, ending shares at Oct. 31, 2020 | 100 | 154,810,655 | |||
Balance, beginning at Jul. 31, 2020 | $ 1,548 | 26,574 | (28,204) | (82) | |
Balance, beginning shares at Jul. 31, 2020 | 100 | 154,810,655 | |||
Net loss | (127) | ||||
Balance, ending at Apr. 30, 2021 | $ 1,548 | 26,574 | (28,331) | (209) | |
Balance, ending shares at Apr. 30, 2021 | 100 | 154,810,655 | |||
Balance, beginning at Oct. 31, 2020 | $ 1,548 | 26,574 | (28,263) | (141) | |
Balance, beginning shares at Oct. 31, 2020 | 100 | 154,810,655 | |||
Net loss | (39) | (39) | |||
Balance, ending at Jan. 31, 2021 | $ 1,548 | 26,574 | (28,302) | (180) | |
Balance, ending shares at Jan. 31, 2021 | 100 | 154,810,655 | |||
Net loss | (29) | (29) | |||
Balance, ending at Apr. 30, 2021 | $ 1,548 | $ 26,574 | $ (28,331) | $ (209) | |
Balance, ending shares at Apr. 30, 2021 | 100 | 154,810,655 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Apr. 30, 2021 | Oct. 31, 2020 | Apr. 30, 2020 | Oct. 31, 2019 | Apr. 30, 2021 | Apr. 30, 2020 | |
Operating activities | ||||||
Net Loss | $ (29) | $ (59) | $ (40) | $ (55) | $ (127) | $ (138) |
Add back: (gain) loss attributable to discontinued operations | (1) | |||||
Changes in operating assets and liabilities | ||||||
Prepaid expenses | (12) | |||||
Accounts payable and accrued expenses | (3) | (1) | ||||
Net cash used in continuing operations | (142) | (140) | ||||
Net cash used in operating activities | (142) | (140) | ||||
Net decrease in cash | (142) | (140) | ||||
Cash, beginning of period | $ 203 | $ 353 | 203 | 353 | ||
Cash, end of period | $ 61 | $ 213 | $ 61 | $ 213 |
Organization and Business
Organization and Business | 9 Months Ended |
Apr. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Business | 1. ORGANIZATION AND BUSINESS Organization. Non-Invasive Monitoring Systems, Inc., a Florida corporation (together with its consolidated subsidiaries, the “Company” or “NIMS”). The Company previously developed and marketed its Exer-Rest ® Business. The Company is currently a shell company (as defined in Rule 12b-2 of the Exchange Act). Discontinued Operations. Accordingly, the Company determined that the assets and liabilities met the discontinued operations criteria in Accounting Standards Codification 205-20-45 and were classified as discontinued operations at April 30, 2021 and July 31, 2020 and for the three and nine months ended April 30, 2021 and 2020. Going Concern 139,000 The Company is seeking potential mergers, acquisitions and strategic collaborations. The Company is also exploring obtaining a promissory note. Equity Exchange Agreement. On August 4, 2019, IRAFG delivered to the Company notice of termination of the Exchange Agreement pursuant to Section 8.01(b)(i) of that agreement due to the failure of the Exchange to have closed on or prior to the Outside Date. No termination fees, penalties or other amounts are payable by the Company in respect of such termination. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Apr. 30, 2021 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation. Discontinued Operations. Discontinued operations expense allocations, consisting of warehouse rent and other inventory related expenses incurred by us, are directly attributed to discontinued operations (see Note 3). Use of Estimates. Cash and Cash Equivalents. Income Taxes. The Company provides for income taxes using an asset and liability-based approach. Deferred income tax assets and liabilities are recorded to reflect the tax consequences in future years of temporary differences between the carrying amounts of assets and liabilities for financial statement and income tax purposes. The deferred tax asset for loss carryforwards and other potential future tax benefits has been fully offset by a valuation allowance since it is uncertain whether any future benefit will be realized. The utilization of the loss carryforward is limited to future taxable earnings of the Company and may be subject to severe limitations if the Company undergoes an ownership change pursuant to the Internal Revenue Code Section 382. Tax years ranging from 2016 to 2020 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. Fair Value of Financial Instruments. Loss Contingencies. Related Parties. Recent Accounting Pronouncements. |
Discontinued Operations
Discontinued Operations | 9 Months Ended |
Apr. 30, 2021 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Discontinued Operations | 3. DISCONTINUED OPERATIONS On May 3, 2019 the Company exchanged its inventory for forgiveness of accrued unpaid rent. Concurrent with the inventory exchange, management with the appropriate level of authority determined to discontinue the operations of the product segment. The detail of the consolidated balance sheets, the consolidated statement of operations and cash flows for the discontinued operations is as stated below (in thousands): As of As of Current liabilities – discontinued operations Accounts payable and accrued expenses $ 50 $ 50 Total current liabilities – discontinued operations 50 50 Total liabilities – discontinued operations $ 50 $ 50 For the three months ended April 30, 2021 For the three months ended April 30, 2020 For the nine months ended April 30, 2021 For the nine months ended April 30, 2020 General and administrative expenses $ - $ - $ - $ (3 ) Gain on write off of accounts payable - - - 4 Gain from discontinued operations $ - $ - $ - $ 1 Basic and diluted income (loss) per common share $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 ) For the three months ended April 30, 2021 For the three months ended April 30, 2020 For the nine months ended April 30, 2021 For the nine months ended April 30, 2020 Cash used in operations for discontinued operations: Gain from discontinued operations $ - $ - $ - $ 1 Gain on write off of accounts payable - - - (4 ) Prepaid expenses - - - 3 Cash used in discontinued operations $ - $ - $ - $ - |
Shareholders' Equity
Shareholders' Equity | 9 Months Ended |
Apr. 30, 2021 | |
Equity [Abstract] | |
Shareholders' Equity | 4. SHAREHOLDERS’ EQUITY The Company has a single class of Preferred Stock. Holders of Series B Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters. Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $100 per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $10 per share, if declared. No preferred stock dividends were declared for the three and nine months ended April 30, 2021 and 2020. The Company did not issue any shares of the Company’s common stock during the three and nine months ended April 30, 2021 and 2020. |
Basic and Diluted Loss Per Shar
Basic and Diluted Loss Per Share | 9 Months Ended |
Apr. 30, 2021 | |
Earnings Per Share [Abstract] | |
Basic and Diluted Loss Per Share | 5. BASIC AND DILUTED LOSS PER SHARE Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the periods ended April 30, 2021 and 2020, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed conversion of preferred stock would be anti-dilutive. |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Apr. 30, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 6. RELATED PARTY TRANSACTIONS Dr. Hsiao, Dr. Frost and directors Steven Rubin and Rao Uppaluri are each stockholders, current or former officers and/or directors or former directors of TransEnterix, Inc. (formerly SafeStitch Medical, Inc.) (“TransEnterix”), a publicly-traded medical device company. The Company’s Chief Financial Officer also served as the Chief Financial Officer of TransEnterix until March 3, 2014, during which he supervised the Miami based accounting staff of TransEnterix under a cost sharing arrangement whereby the total salaries of the Miami based accounting staff was shared by the Company and TransEnterix. The Chief Financial Officer continues to serve as the Chief Financial Officer of Cocrystal Pharma, Inc., a clinical stage biotechnology company, and in which Steve Rubin, serves on the Board. Since December 2009, the Company’s Chief Legal Officer has served under a similar cost sharing arrangement as the Chief Legal Officer of TransEnterix. The Company expensed $1,200 during the three months ended April 30, 2021 and 2020 and $3,600 during the nine months ended April 30, 2021 and 2020 under the cost sharing arrangement. At April 30, 2021 and July 31, 2020, the Company had an accounts payable liability of $400 and $400 under the cost sharing arrangement, respectively. The Company signed a five year lease for office space in Miami, Florida with a company controlled by Dr. Phillip Frost, who is the beneficial owner of more than 10% of the Company’s common stock. The rental payments under the Miami office lease, which commenced January 1, 2008 and expired on December 31, 2012, were approximately $1,250 per month and then continued on a month-to-month basis. In February 2016 the rent was reduced to $0 per month. For the three and nine months ended April 30, 2021 and 2020, the Company did not record any rent expense related to the Miami lease. At April 30, 2021 and July 31, 2020 there was no rent payable. The Company is under common control with multiple entities and the existence of that control could result in operating results or financial position of each individual entity significantly different from those that would have been obtained if the entities were autonomous. One of those related parties, OPKO Health, Inc. (“OPKO”) and the Company are under common control and OPKO has a one percent ownership interest in the Company that OPKO has accounted for as an equity method investment due to the ability to significantly influence the Company. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Apr. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 7. COMMITMENTS AND CONTINGENCIES Leases. The Company was under an operating lease agreement for our corporate office space that expired in 2012. The lease currently continues on a month to month basis at no cost. COVID-19. Current economic conditions with COVID-19 have been, and continue to be, volatile and continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business and to replace, in a timely manner, maturing liabilities or to successfully examine strategic alternatives. Quarantines would make our ability to look for strategic alternatives more difficult and prospects of borrowing or equity raises would be more challenging. Additionally, the sales of equity or convertible debt securities may result in dilution to our stockholders. Product Development and Supply Agreement. In September 2007, the Company entered into a Product Development and Supply Agreement (the “Agreement”) with Sing Lin Technologies Co. Ltd., a company based in Taichung, Taiwan (“Sing Lin”). Pursuant to the Agreement, the Company consigned to Sing Lin the development and design of the next generation Exer-Rest and related devices. The Agreement commenced as of September 3, 2007 and had a term that extended three years from the acceptance by NIMS of the first run of production units. Thereafter, the Agreement automatically renewed for successive one year terms unless either party sent the other a notice of non-renewal. Either party was permitted to terminate the Agreement with ninety days prior written notice. Upon termination, each party’s obligations under the Agreement were to be limited to obligations related to confirmed orders placed prior to the termination date. Pursuant to the Agreement, Sing Lin designed, developed and manufactured the tooling required to manufacture the acceleration therapeutic platforms for a total cost to the Company of $471,000. Sing Lin utilized the tooling in the performance of its production obligations under the Agreement. The Company paid Sing Lin $150,000 of the tooling cost upon execution of the Agreement and $150,000 upon the Company’s approval of the product prototype concepts and designs. The balance of the final tooling cost became due and payable in September 2008 upon acceptance of the first units produced using the tooling, and was paid in full during the year ended July 31, 2009. Under the now-terminated Agreement, the Company also granted Sing Lin the exclusive distribution rights for the products in certain countries in the Far East, including Taiwan, China, Japan, South Korea, Malaysia, Indonesia and certain other countries. Sing Lin agreed not to sell the Products outside its geographic areas in the Far East. The Agreement provided for the Company to purchase approximately $2.6 million of Exer-Rest units within one year of the September 2008 acceptance of the final product. The Agreement further provided for the Company to purchase $4.1 million and $8.8 million of Exer-Rest products in the second and third years following such acceptance, respectively. These minimum purchase amounts were based upon 2007 product costs multiplied by volume commitments. Through April 30, 2021, the Company had paid Sing Lin $1.7 million in connection with orders placed through that date. As of April 30, 2021, the Company has approximately $41,000 of payables due to Sing Lin. As of April 30, 2021, aggregate minimum future purchases under the Agreement totaled approximately $13.9 million. As of April 30, 2021, the Company had not placed orders sufficient to meet the purchase obligations under the Agreement. The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. As of the date of this filing, Sing Lin has not followed up on its July 2010 demand. There can be no assurance that Sing Lin will not attempt to enforce its remedies under the Agreement, or pursue other potential remedies. The Company believes that Sing Lin in no longer in business. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Apr. 30, 2021 | |
Accounting Policies [Abstract] | |
Consolidation | Consolidation. |
Discontinued Operations | Discontinued Operations. Discontinued operations expense allocations, consisting of warehouse rent and other inventory related expenses incurred by us, are directly attributed to discontinued operations (see Note 3). |
Use of Estimates | Use of Estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents. |
Income Taxes | Income Taxes. The Company provides for income taxes using an asset and liability-based approach. Deferred income tax assets and liabilities are recorded to reflect the tax consequences in future years of temporary differences between the carrying amounts of assets and liabilities for financial statement and income tax purposes. The deferred tax asset for loss carryforwards and other potential future tax benefits has been fully offset by a valuation allowance since it is uncertain whether any future benefit will be realized. The utilization of the loss carryforward is limited to future taxable earnings of the Company and may be subject to severe limitations if the Company undergoes an ownership change pursuant to the Internal Revenue Code Section 382. Tax years ranging from 2016 to 2020 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments. |
Loss Contingencies | Loss Contingencies. |
Related Parties | Related Parties. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements. |
Discontinued Operations (Tables
Discontinued Operations (Tables) | 9 Months Ended |
Apr. 30, 2021 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Schedule of Balance Sheets of Discontinued Operations | As of As of Current liabilities – discontinued operations Accounts payable and accrued expenses $ 50 $ 50 Total current liabilities – discontinued operations 50 50 Total liabilities – discontinued operations $ 50 $ 50 |
Schedule of Statements of Operations for Discontinued Operations | For the three months ended April 30, 2021 For the three months ended April 30, 2020 For the nine months ended April 30, 2021 For the nine months ended April 30, 2020 General and administrative expenses $ - $ - $ - $ (3 ) Gain on write off of accounts payable - - - 4 Gain from discontinued operations $ - $ - $ - $ 1 Basic and diluted income (loss) per common share $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 ) |
Schedule of Cash Flows of Discontinued Operations | For the three months ended April 30, 2021 For the three months ended April 30, 2020 For the nine months ended April 30, 2021 For the nine months ended April 30, 2020 Cash used in operations for discontinued operations: Gain from discontinued operations $ - $ - $ - $ 1 Gain on write off of accounts payable - - - (4 ) Prepaid expenses - - - 3 Cash used in discontinued operations $ - $ - $ - $ - |
Organization and Business (Deta
Organization and Business (Details Narrative) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Apr. 30, 2021 | Apr. 30, 2020 | Apr. 30, 2021 | Apr. 30, 2020 | Jul. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||
Net losses from continuing operation | $ (29) | $ (40) | $ (127) | $ (139) | |
Accumulated deficit | (28,331) | (28,331) | $ (28,204) | ||
Cash | 61 | 61 | $ 203 | ||
Working capital deficit | $ (209) | $ (209) |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands | Apr. 30, 2021 | Jul. 31, 2020 |
Accounting Policies [Abstract] | ||
Cash | $ 61 | $ 203 |
Cash equivalents |
Discontinued Operations - Sched
Discontinued Operations - Schedule of Balance Sheets of Discontinued Operations (Details) - USD ($) $ in Thousands | Apr. 30, 2021 | Jul. 31, 2020 |
Discontinued Operations and Disposal Groups [Abstract] | ||
Accounts payable and accrued expenses | $ 50 | $ 50 |
Total current liabilities - discontinued operations | 50 | 50 |
Total liabilities - discontinued operations | $ 50 | $ 50 |
Discontinued Operations - Sch_2
Discontinued Operations - Schedule of Statements of Operations for Discontinued Operations (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Apr. 30, 2021 | Apr. 30, 2020 | Apr. 30, 2021 | Apr. 30, 2020 | |
Discontinued Operations and Disposal Groups [Abstract] | ||||
General and administrative expenses | $ (3) | |||
Gain on write off of accounts payable | 4 | |||
Gain from discontinued operations | $ 1 | |||
Basic and diluted income (loss) per common share | $ 0 | $ 0 | $ 0 | $ 0 |
Discontinued Operations - Sch_3
Discontinued Operations - Schedule of Cash Flows of Discontinued Operations (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Apr. 30, 2021 | Apr. 30, 2020 | Apr. 30, 2021 | Apr. 30, 2020 | |
Discontinued Operations and Disposal Groups [Abstract] | ||||
Gain from discontinued operations | $ 1 | |||
Gain on write off of accounts payable | (4) | |||
Prepaid expenses | 3 | |||
Cash used in discontinued operations |
Shareholders' Equity (Details N
Shareholders' Equity (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Apr. 30, 2021 | Apr. 30, 2020 | Apr. 30, 2021 | Apr. 30, 2020 | |
Subsidiary, Sale of Stock [Line Items] | ||||
Dividends, preferred stock | ||||
Stock issued during the period | ||||
Series B Preferred Stock [Member] | ||||
Subsidiary, Sale of Stock [Line Items] | ||||
Preferred stock liquidation preference, per share value | $ 100 | $ 100 | ||
Dividends payable amount per share | $ 10 | $ 10 |
Basic and Diluted Loss Per Sh_2
Basic and Diluted Loss Per Share (Details Narrative) - shares | 9 Months Ended | |
Apr. 30, 2021 | Apr. 30, 2020 | |
Earnings Per Share [Abstract] | ||
Antidilutive securities excluded from computation of earnings per share |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | Jan. 02, 2008 | Feb. 29, 2016 | Apr. 30, 2021 | Apr. 30, 2020 | Apr. 30, 2021 | Apr. 30, 2020 | Jul. 31, 2019 | Jul. 31, 2020 |
Dr. Phillip Frost [Member] | ||||||||
Lease term | 5 years | |||||||
Lease expired date | Dec. 31, 2012 | |||||||
Rental payments | $ 1,250 | |||||||
Reduced amount in rental payments | $ 0 | |||||||
Rent expense | ||||||||
Dr. Phillip Frost [Member] | Minimum [Member] | ||||||||
Beneficial ownership percentage | 10.00% | |||||||
Cost Sharing Arrangement [Member] | ||||||||
Costs and expenses related party | 1,200 | $ 1,200 | 3,600 | $ 3,600 | ||||
Accounts payable related parties | $ 400 | $ 400 | $ 400 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands | 1 Months Ended | 9 Months Ended |
Sep. 30, 2007 | Apr. 30, 2021 | |
Lease expiration, date | 2012 | |
Purchase obligation | $ 13,900 | |
Purchase obligations commitments | The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. | |
Sing Lin Technologies [Member] | ||
Payments to suppliers | $ 1,700 | |
Payables to customers | 41 | |
Product Development and Supply Agreement [Member] | Exer-Rest units [Member] | ||
Purchase obligation, due in next twelve months | 2,600 | |
Purchase obligation, due in second year | 4,100 | |
Purchase obligation, due in third year | $ 8,800 | |
Product Development and Supply Agreement [Member] | Sing Lin Technologies Co. Ltd. [Member] | ||
Manufacturing costs | $ 471 | |
Tooling cost | 150 | |
Payments on approval of product prototype concepts and designs | $ 150 |